Core Thesis - Alphatec Holdings, Inc. (ATEC) presents a bearish investment thesis due to structural headwinds and material downside risks over the next 12 months, particularly following its 4Q'25 results [3][6] Company Overview - ATEC is a medical technology company focused on surgical treatments for spinal disorders, operating both in the United States and internationally [3] Market Dynamics - The company's flagship Prone TransPsoas (PTP) approach to lumbar fusion only addresses a subset of the spinal surgery market, with approximately 19% of fusion-eligible patients unable to use PTP and another 25-33% for whom it is non-ideal [3] - A significant portion of the target population, particularly those with spinal stenosis or herniated discs, either do not require fusion or are better served with decompression procedures, reducing the effective total addressable market to roughly $6 billion, which is about 42% below bullish estimates [4] Regulatory Environment - Regulatory pressures, such as CMS's WISER AI-driven pre-authorization for outpatient fusions, further constrain volumes, especially as outpatient procedures have increased from 2% to 26% of the market [4] Competitive Landscape - Competitor products have achieved technological parity, with ATEC lagging in surgical robotics and overall device functionality, which undermines its previous competitive advantage and limits future case growth [5] - The newly launched Valence robot is considered less capable than offerings from competitors like Medtronic, Globus, and Vista, leading to expectations of slow adoption [5] Financial Outlook - Recent growth in ATEC's sales was largely driven by elevated sales commissions, which are now being normalized, suggesting potential sales rep churn in FY'26 that could threaten surgical volume and market share [5] - Valuation multiples are expected to compress as ATEC faces decelerating sales growth, pricing pressure, and shrinking market opportunities, with a base-case target price of $14.2 indicating approximately 33% downside from current levels [6] - The company is viewed as a high-conviction short with substantial downside potential relative to its current market price [6]

Core Thesis - Alphatec Holdings, Inc. (ATEC) presents a bearish investment case due to structural headwinds and material downside risks over the next 12 months, particularly following its 4Q'25 results [3][6] Company Overview - ATEC is a medical technology company focused on surgical treatments for spinal disorders, operating both in the United States and internationally [3] Market Limitations - The flagship Prone TransPsoas (PTP) approach addresses only a subset of the spinal surgery market, with approximately 19% of fusion-eligible patients unable to use PTP and another 25-33% for whom it is non-ideal [3] - A significant portion of the target population, particularly those with spinal stenosis or herniated discs, either do not require fusion or are better served with decompression procedures, reducing the effective total addressable market to roughly $6 billion, which is about 42% below bullish estimates [4] Regulatory Challenges - Regulatory pressures, such as CMS's WISER AI-driven pre-authorization for outpatient fusions, further constrain volumes, especially as outpatient procedures have increased from 2% to 26% of the market [4] Competitive Landscape - Competitor products have achieved technological parity, with ATEC lagging in surgical robotics and overall device functionality, undermining its previous competitive advantage and limiting future growth [5] - The newly launched Valence robot is considered less capable than offerings from competitors like Medtronic, Globus, and Vista, leading to expectations of slow adoption [5] Sales and Growth Concerns - Recent growth was primarily driven by elevated sales commissions, which are now being normalized, indicating potential sales rep churn in FY'26 that could threaten surgical volume and market share [5] - Valuation multiples are expected to compress as ATEC faces decelerating sales growth, pricing pressure, and shrinking market opportunities, with a base-case target price of $14.2 implying approximately 33% downside from current levels [6]

Summary of Alphatec FY Conference Call (March 11, 2026) Company Overview - **Company**: Alphatec (NasdaqGS: ATEC) - **Industry**: Spine Surgery and Medical Devices Key Points Market Position and Growth Opportunities - Alphatec has made significant progress in the past year, addressing previous concerns regarding capital deployment, financing, and EBITDA, ending the year with strong cash flows and EBITDA [3][4] - The spine surgery market presents substantial growth opportunities, with Alphatec positioned as a smaller player amidst market share shifts among larger competitors [4][12] - The company believes that improving surgical outcomes through better technology will drive market share growth, as high revision rates in spine surgery indicate room for improvement [9][10] Surgeon Adoption and Utilization Metrics - Surgeon adoption rates have been around 20% over the last eight quarters, with a notable 23% in Q4 [21] - New surgeon users tend to drive mid-double-digit volume growth in subsequent years, indicating a long-term utilization improvement [21] - The average selling price (ASP) for cases is expected to grow at a low single-digit rate, reflecting increased complexity in surgeries as surgeons gain experience with Alphatec's products [22][27] Financial Performance and Cash Flow Management - The company achieved a 41% drop-through to reach approximately 12% adjusted EBITDA last year, with a guidance of 32% drop-through for the current year [64][65] - Effective management of inventory and asset deployment is crucial for supporting growth, with a target of 75 cents on the growth dollar basis [65][66] Competitive Landscape and Rep Dynamics - The competitive environment has been influenced by major players like Stryker and J&J making strategic moves, which has lowered the friction for rep transitions and increased the availability of talent [32][41][45] - The selection of new reps reflects the overall market share dynamics, with no significant over-indexing from any particular competitor [39] Technological Innovations - Alphatec is investing in enabling technologies, such as the Valence robot, which aims to enhance surgical precision and efficiency, particularly in complex procedures [50][58] - The Valence robot is positioned at a competitive price point, making it accessible for both large academic settings and community hospitals [58] Conclusion - Alphatec is confident in its growth trajectory, driven by improved surgeon adoption, innovative technologies, and effective cash flow management strategies. The company is well-positioned to capitalize on the evolving landscape of the spine surgery market [8][12][66]

Financial Data and Key Metrics Changes - The company reported a cash usage of $5 million in Q2, at the high end of the guidance range, and expects to achieve slightly positive free cash flow for the year [4][5] - The guidance for top-line growth has been raised to approximately 21% for the year, with expectations of $130 million in total revenue for 2023, 2024, and 2025 [10][12] Business Line Data and Key Metrics Changes - The company achieved a 21% increase in new surgeon adds in Q2, maintaining a consistent growth rate over the past eight quarters [15] - Existing territories grew by 29% in Q2, indicating strong demand and interest from surgeons [19] Market Data and Key Metrics Changes - The company anticipates a slight step down in market performance from Q2 to Q3, followed by a rebound in Q4 [10] - The two-year stack growth rate for Q1 was approximately $31 million, and for Q2 it was about $34 million, with expectations of $33 million for each quarter in the second half [11][12] Company Strategy and Development Direction - The company is focused on compelling surgeons with unique clinical solutions and aims to expand its market share in the spine sector [15] - The upcoming launch of the Valence robot is expected to address clinical challenges in spine surgery, with a focus on integrating it with existing procedures [33][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving free cash flow profitability in 2025, citing better-than-expected performance in the first half of the year [4][5] - The company is optimistic about strong surgeon adoption rates, which are expected to drive procedural volume growth [31] Other Important Information - The company plans to maintain a narrow and deep international strategy, focusing on profitable markets like Australia, New Zealand, and Japan [55][56] - The PTP Corpectomy launch is seen as a natural evolution within the PTP ecosystem, aimed at enhancing clinical value and procedural volume [61][62] Q&A Session Summary Question: What investor feedback have you received since Q2 results? - Investors are focused on the durability of top-line growth and the company's profitability profile [3] Question: What gives you confidence in achieving free cash flow profitability in 2025? - Confidence stems from better-than-expected cash flow performance in the first half of the year [4] Question: How do you see the rest of the year playing out from a cash flow perspective? - Expectations for Q3 are a free cash flow generation of $1 million to $5 million, with high single digits anticipated in Q4 [9] Question: Can you discuss the overall spine market and recruitment efforts? - The company is benefiting from market disruptions and is onboarding sales representatives to support surgeon interest [14] Question: What are the key performance metrics for new sales reps? - New reps typically ramp up over a two-year period, with significant revenue growth expected by year three [21][22] Question: How do you balance attracting new sales talent while achieving cash flow positivity? - The company has a structured investment approach, spending $0.75 for every dollar of year-over-year growth [27][28] Question: What are your international plans for 2025 and beyond? - The focus remains on Australia, New Zealand, and Japan, with plans for growth and profitability in these markets [55][56] Question: How does the PTP Corpectomy fit into the broader ecosystem? - It is seen as a natural evolution that adds clinical value and supports procedural volume growth [61][62]